SCD411 for Age-Related Macular Degeneration

Not yet recruiting at 3 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a single-arm, multicenter study to evaluate clinical usability of a pre-filled syringe containing SCD411 in adult patients with neovascular Wet Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), or Diabetic Retinopathy (DR)

Who Is on the Research Team?

BJ

Byung Jhip Ha

Principal Investigator

Sam Chun Dang Pharm. Co. Ltd.

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.
* Be capable of understanding the written informed consent and signed informed consent (patient or legally authorized representative)
* Be an ophthalmologist with a retinal specialty or with IVT training
See 7 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants use the SCD411 prefilled syringe for treatment of their condition

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • SCD411

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: SCD411Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Sam Chun Dang Pharm. Co. Ltd.

Lead Sponsor

Trials
1
Recruited
580+